This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Type 2 Diabetes Mellitus (T2DM) is a rapidly growing global health problem with increasing prevalence. from 2016‐2019 and secondary diagnosis of T2DM. from 2016‐2019 and secondary diagnosis of T2DM. Of those patients, 35.43% (n=273,993) were diabetic and 64.57% (n=151,112) were non‐diabetic.
Between 2016 and 2018, 3285 MESA participants from 6 field centers underwent comprehensive speckle-tracking echocardiography with passive leg raise maneuver, Kansas City Cardiomyopathy Questionnaire, 6-minute walk test, arterial stiffness assessment, and proteomics (including NT-proBNP [N-terminal pro-B-type natriuretic peptide]).Results:Median
The National Inpatient Sample (NIS) database from 2016‐2019 for patients with a principal diagnosis of AIS using the ICD‐10 code I63 was queried. Outcome measures studied included prolonged length of stay (LOS), discharge disposition, and inpatient mortality.ResultsWe identified 2,939,160 patients with AIS between 2016 and 2019.
Just for clarity, type 2 diabetes is when insulin resistance progresses to the point that your body can no longer keep your blood glucose levels under control. So if you have type 2 diabetes, you, by definition, are insulin resistant. For each additional feature, the likelihood and likely severity of insulin resistance increases.
BackgroundMeta‐analyses of large clinical trials investigating SGLT2 (sodium‐glucose cotransporter‐2) inhibitors have suggested their protective effects against atrialfibrillation in patients with type 2 diabetes. An active‐comparator, new‐user design was used, and the 2 groups of patients were matched using propensity scores.
This study aims to address this gap by examining the association between MA and 90-day AIS readmission.Methods:Using the National Readmission Database between 2016 and 2019, we identified patients admitted with a principal or non-principal diagnosis of migraine. Within 90 days, 411,850 (0.39%) patients had a subsequent admission for AIS.
0.90], P<0.001), history of atrialfibrillation (OR, 1.27 [95% CI, 1.01-1.60], 1.60], P<0.001), and absence of diabetes (OR, 0.77 [95% CI, 0.60-0.98], Patient and hospital-level characteristics associated with use and outcome of reperfusion therapies were analyzed. 0.98], P<0.001).Conclusions:In
We used a mixed effects linear regression model to examine the relationship between DTD group and length of stay, controlling for age, race, sex, last known well to arrival time, initial NIHSS, atrialfibrillation, and alcohol/drug abuse and clustering by hospital site.
Characteristics associated with intracranial stent utilization were male sex, history of diabetes, hypertension, or chronic kidney disease, absence of atrialfibrillation or CHF, and southern US region. Patient- and hospital-level characteristics were analyzed. women; mean age, 69.1 [SD, years; mean NIHSS score of 15.1 [SD,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content